Form 4: Enanta Pharma CBO Granted 90,000 Stock Options

Enanta Pharmaceuticals' Chief Business Officer, Brendan Luu, was granted 90,000 stock options with an exercise price of $13.66.

Summary

• Brendan Luu, Chief Business Officer of Enanta Pharmaceuticals Inc. (ENTA), was granted 90,000 stock options.
• The stock options have an exercise price of $13.66 per share.
• The grant date for these options was November 25, 2025.
• The options will vest quarterly in substantially equal installments over four years from the grant date, subject to continued employment.
• The expiration date for these stock options is November 25, 2035.
• Following this transaction, Mr. Luu beneficially owns 90,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive event as it aligns management's interests with shareholders, incentivizing long-term performance. However, it is a compensation event rather than a direct indicator of immediate financial performance or operational success.

Positives

• The grant of 90,000 stock options to the Chief Business Officer aligns management's long-term interests with those of shareholders, incentivizing future company performance.
• The options have a 10-year expiration period, providing a significant window for potential value realization based on stock price appreciation.

Negatives

• The value of the stock options is contingent on the company's stock price exceeding the exercise price of $13.66, meaning there is no guaranteed value if the stock underperforms.

Future Outlook

The stock option grant serves as a forward-looking incentive for the Chief Business Officer, aligning his compensation with the company's future stock performance and long-term value creation.

Industry Context

The granting of stock options to key executives is a standard practice in the biotechnology and pharmaceutical industries, used to attract, retain, and motivate talent by linking their personal wealth to the company's long-term success and shareholder value.

Comparison to Industry Standards

• Executive stock option grants are a common component of compensation packages across the biotech and pharma sectors, comparable to practices at companies like Gilead Sciences, Moderna, or Pfizer, which frequently use equity incentives to align executive interests with shareholder returns.
• The vesting schedule of quarterly installments over four years is a typical industry standard designed to encourage long-term commitment and performance from executives.

Stakeholder Impact

• Shareholders: Potential positive impact as executive compensation is tied to stock performance, aligning management's incentives with shareholder value creation.
• Employees (Brendan Luu): Direct financial incentive tied to the company's future stock price performance, enhancing motivation and retention.

Next Steps

• Brendan Luu's continued employment is required for the stock options to vest according to the quarterly schedule over four years.

Key Dates

Keywords

ENANTA PHARMACEUTICALS, ENTA, Stock Option, Executive Compensation, Insider Transaction, Brendan Luu, Form 4